It’s ‘GAIM’ on for Neurophage with $17M series D
By Marie Powers
Tuesday, March 25, 2014
Neurophage Pharmaceuticals Inc. moved one step closer to an investigational new drug filing and the initiation of human studies for lead candidate, NPT088, with the completion of a $17 million series D.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.